Meet the Management Team

Our leadership team is responsible for the strategic direction and management of Liminal BioSciences. They are assisted in these responsibilities by our board and advisory members. Each member of the management team is responsible for a specific part of our business.

Bruce Pritchard, BA, CA, FioD
Chief Executive Officer
Patrick Sartore, B.Sc., LLB.
President
Marie Iskra, LL.B.
General Counsel
Dr. Gary Bridger
Board Member and Strategic Scientific Adviser
Dr. Jeffrey Smith
Strategic Medical Adviser
Bruce Pritchard, BA, CA, FioD
Chief Executive Officer

Bruce was appointed as Chief Executive Officer, effective 13 November 2020. Prior to that he was one of 2 Chief Operating Officers In this role he was responsible for the company’s discovery, clinical development, program management, CMC and business development functions related to Small Molecule Therapeutics.

An accountant by training, he has spent over two decades working in the life sciences and pharmaceutical industry. He has more than fourteen years’ experience with Liminal and has held a number of senior global positions across the organisation.

Prior to being appointed CEO he became COO in 2014, previously he was the Group CFO, a role he had held since 2008. Bruce brings a proven track record of success in strategic acquisitions and in raising debt and equity finance.

As well as being a chartered accountant, Bruce also brought to the role many years of experience in general management and operations. Prior to joining Liminal, Bruce worked as a senior director for CV Therapeutics, a NASDAQ listed biopharmaceutical company.

Bruce is a graduate of Heriot-Watt University where he gained a BA in Accountancy and Computer Science. He is a member of the Institute of Chartered Accountants of Scotland and a Fellow of the Institute of Directors. He is also a Non-Executive Director and Chair of the Audit Committee of Porton Biopharma Limited, and is Deputy President of The Institute of Chartered Accountants of Scotland.

Bruce is based out of Liminal’s UK office in Cambridge.

Patrick Sartore, B.Sc., LLB.
President

Patrick was appointed as President, effective November 13, 2020. Prior to that, he was one of two Chief Operating Officers. In this role, Patrick was responsible for the company’s commercial, marketing, clinical development, manufacturing, and corporate & business development functions, related to Plasma-Derived Therapeutics . A lawyer by training, he has spent over 18 years working in the life sciences and pharmaceutical industry. He has more than fourteen years’ experience with Liminal and has held a number of senior global positions across the organization.

Prior to being appointed COO in 2019, Patrick was the Group Chief Legal Officer and Corporate Secretary, a role he had held since 2015. Patrick brings a proven track record of success in strategic acquisition and licensing transactions and in closing debt and equity financings in various jurisdictions.

As well as being a lawyer, Patrick also brought to the role many years of experience in general intellectual property management, prosecution, commercialization as well as VC financing. Prior to joining Liminal, Patrick worked as a senior counsel for Univalor, a commercialization and VC investment vehicle for life science companies spun out of various Canadian hospitals, institutions and academia. Patrick was also previously employed by Leger Robic Richard, L.L.P., a firm specializing in Intellectual Property, Corporate and Commercial Law, as an attorney.

Mr. Sartore graduated from the University of Montreal with a Bachelor of Law (LLB) in 1999 and was called to the Bar of Québec in 2001. Mr. Sartore also holds a Bachelor of Science (BSc), with Distinction, from Concordia University and a specialized graduate diploma (DESS) from HEC Montréal, in Tax.

Marie Iskra, LL.B.
General Counsel

Marie is General Counsel for the Liminal Group. As General Counsel Marie oversees the legal, compliance, intellectual property and corporate governance functions. Marie is also Corporate Secretary for Liminal.

Dr. Gary Bridger
Board Member and Strategic Scientific Adviser

Dr. Bridger has extensive experience in leading research and development through to commercialisation. Dr. Bridger previously served as Executive Vice President of Research and Development at Xenon Pharmaceuticals Inc., Senior Vice President of Research and Development of Genzyme Corporation and co-founded AnorMED Inc., eventually acquired by Genzyme.

Dr. Jeffrey Smith
Strategic Medical Adviser

Dr. Smith has held many senior positions within the pharmaceutical industry, most recently, Managing Director of Alder Biopharmaceuticals Inc. Dublin, Ireland and before that Senior Vice President, Translational Medicine at Alder Biopharmaceuticals Inc, Seattle. Dr. Smith was responsible for the clinical development (phase I – III) of eptinezumab (anti-CGRP antibody for migraine) and clazakizumab (anti -IL-6 antibody for rheumatoid arthritis and cancer cachexia). Dr. Smith was also a founder of Alder Biopharmaceutcials Inc.